Dendreon (NASDAQ: DNDN) is a Seattle based biotechnology company. Its lead product candidate, Sipuleucel-T (known as Provenge during drug trials), is an immunotherapy for prostate cancer. Provenge (sipuleucel-T) consists of a mixture of the patient's own blood cells (autologous, with dendritic cells thought to be the most important) that have been incubated with the Dendreon PAP-GM-CSF fusion protein. Phase III clinical trial results demonstratin...
more
Dendreon (NASDAQ: DNDN) is a Seattle based biotechnology company. Its lead product candidate, Sipuleucel-T (known as Provenge during drug trials), is an immunotherapy for prostate cancer. Provenge (sipuleucel-T) consists of a mixture of the patient's own blood cells (autologous, with dendritic cells thought to be the most important) that have been incubated with the Dendreon PAP-GM-CSF fusion protein. Phase III clinical trial results demonstrating a survival benefit for prostate cancer patients receiving the drug were presented at the AUA meeting on April 28, 2009.
Dendreon's name derives from the "Dendritic Cell" which forms a major component, but not the only component, of product candidates that use the Dendreon "Cassette Technology" to insert a disease-specific target protein into a general platform. Their lead product candidate Provenge (now known as Sipuleucel T) is one example of their rationally designed therapeutic process designed to break immune tolerance to certain disease...
less
